Trade Gilead Sciences Inc - GILD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 64.59 |
| Open | 64.59 |
| 1-Year Change | -18.05% |
| Day's Range | 64.52 - 66.13 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 9, 2024 | 64.52 | -0.59 | -0.91% | 65.11 | 65.32 | 64.46 |
| May 8, 2024 | 64.95 | -0.83 | -1.26% | 65.78 | 65.96 | 64.71 |
| May 7, 2024 | 65.50 | 0.37 | 0.57% | 65.13 | 66.09 | 64.95 |
| May 6, 2024 | 64.96 | 0.23 | 0.36% | 64.73 | 65.50 | 64.29 |
| May 3, 2024 | 64.65 | -0.42 | -0.65% | 65.07 | 65.75 | 64.27 |
| May 2, 2024 | 64.95 | -0.51 | -0.78% | 65.46 | 65.75 | 64.83 |
| May 1, 2024 | 65.38 | 0.91 | 1.41% | 64.47 | 65.83 | 64.47 |
| Apr 30, 2024 | 64.97 | -0.72 | -1.10% | 65.69 | 66.13 | 64.75 |
| Apr 29, 2024 | 65.91 | 0.72 | 1.10% | 65.19 | 66.85 | 64.05 |
| Apr 26, 2024 | 65.41 | 0.42 | 0.65% | 64.99 | 66.15 | 64.56 |
| Apr 25, 2024 | 65.10 | -1.63 | -2.44% | 66.73 | 67.79 | 63.72 |
| Apr 24, 2024 | 67.06 | 0.47 | 0.71% | 66.59 | 67.67 | 65.85 |
| Apr 23, 2024 | 66.60 | -0.07 | -0.10% | 66.67 | 67.62 | 66.45 |
| Apr 22, 2024 | 66.81 | 0.10 | 0.15% | 66.71 | 67.51 | 66.45 |
| Apr 19, 2024 | 66.71 | 0.98 | 1.49% | 65.73 | 66.77 | 65.73 |
| Apr 18, 2024 | 66.18 | -0.62 | -0.93% | 66.80 | 67.16 | 65.85 |
| Apr 17, 2024 | 66.84 | -0.43 | -0.64% | 67.27 | 67.48 | 66.84 |
| Apr 16, 2024 | 67.27 | -0.21 | -0.31% | 67.48 | 67.78 | 67.13 |
| Apr 15, 2024 | 67.62 | -0.17 | -0.25% | 67.79 | 68.51 | 67.62 |
| Apr 12, 2024 | 67.84 | -0.31 | -0.45% | 68.15 | 68.64 | 67.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the NASDAQ-100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com